Royal Philips reported EUR 3.9bn in Q1 sales, 6% order intake growth and FDA clearances for four AI-powered imaging systems, reiterating its full

The SynCardia parent raises $5m via shares and warrants at $0.30, using proceeds to repay senior secured notes and support working capital.

Idorsia's 2026 AGM approved three new board members and reaffirmed Jean-Paul Clozel as chairman, with a CEO search ongoing.

Topband-backed Simple Charm claims professional-grade precision for home beauty devices via AI facial recognition and ultrasonic technology.

Taysha Gene Therapies confirmed FDA alignment on its BLA submission route for TSHA-102, with pivotal trial dosing on track to complete in Q2 2026.

TPST-2003 achieved complete responses in all 15 CAR-T-naïve evaluable patients across two Phase 1 trials, with Tempest now targeting FDA talks on

The payer agreement covers roughly 20% of US commercial lives for TONMYA, the first new fibromyalgia treatment approved in more than 15 years.

The US nonprofit has launched a centralised education and care navigation platform for organ and stem cell transplant patients, backed by 25 leading transplant centres.

The UCLA-founded biotech will show preclinical data on its dCK inhibitor TRE-515 in optic neuritis at a Los Angeles summit on 21 May.

TScan Therapeutics plans to initiate its pivotal ALLOHA-2 study of TSC-101 in haematological malignancies this quarter, backed by $128m in cash.

UroGen posted $29.2m in ZUSDURI sales in Q1 2026, up 109% quarter-on-quarter, as a permanent J Code unlocked broader reimbursement access.

Phase 2 data show VP-315 reduced untreated basal cell carcinoma lesions by 67%, suggesting a systemic immune response beyond the injection site.